Navigation Links
Texas Cardiac Arrhythmia Institute at St. David's Medical Center Selected to Conduct Clinical Trial for Device to Treat Atrial Fibrillation

AUSTIN, Texas, Oct. 7 /PRNewswire/ -- The Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center has been selected as one of only a few sites in the nation to participate in an FDA-approved clinical trial for a new device to treat persistent atrial fibrillation. TCAI, an international treatment, training and research center specializing in heart rhythm disorders, is a partnership between St. David's Medical Center and Texas Cardiovascular Consultants.

"This is just another example of how TCAI is leading the nation in pioneering new treatments for atrial fibrillation," Dr. Rodney Horton, electrophysiologist, Texas Cardiac Arrhythmia, said. "We are proud to take part in this study that has the potential to greatly enhance the future treatment of A Fib."

Heart arrhythmias are very common, affecting more than two million people nationwide. Atrial fibrillation, or A Fib, is the most common heart arrhythmia. A Fib is a rhythm disorder that affects the electrical system, or "wiring," of the heart muscle. It is often treated with cardiac ablation -- a procedure that allows physicians to deliver energy directly to the heart muscle at precise points that trigger the arrhythmia, creating a lesion that blocks the pathway for the abnormal heart rhythm. The new study involves second generation software (Gen II) that uses a catheter believed to result in the formation of a more effective lesion.

"In the Gen II study, we are evaluating a revolutionary radiofrequency ablation catheter," Dr. Horton said. "This device is able to monitor the temperature at its tip, giving electrophysiologists the ability to better control the delivery of energy through the catheter and generate a more effective lesion." In traditional cardiac ablation, room temperature saline is injected through the catheter prior to the delivery of energy. Because standard catheters do not measure the temperature at the catheter's tip, overheating may occur, resulting in the generation of a less effective lesion.

"While many studies involve less complex cases, we were particularly interested in this one because participants must experience more severe atrial fibrillation," Horton said. "The study incorporates the technology that we already know is effective and advances it to an even higher level, helping us generate a consistently effective lesion in highly complicated cases."

The study is designed for patients who have persistent A Fib. Participants must also meet other specific criteria. To inquire about participation in the clinical trail, please call 512-544-2342.

Texas Cardiac Arrhythmia

Texas Cardiac Arrhythmia, a division of Texas Cardiovascular Consultants, was founded in 1996 by Rodney Horton, M.D. The practice has grown to include nine clinical electrophysiologists specializing in the area of heart rhythm disturbances. Texas Cardiac Arrhythmia Research, a division of Texas Cardiovascular Consultants, is committed to providing opportunities for patients in Central Texas to participate in studies utilizing the latest technology in the area of cardiac electrophysiology.

St. David's Medical Center

Since 1924, St. David's Medical Center has provided quality medical care to the residents of Central Texas. Conveniently located in central Austin at 32nd Street and IH-35, St. David's Medical Center provides comprehensive care with special expertise in neurology and neurosurgery, cardiac services, bariatric surgery, orthopedics, maternity and newborn services and rehabilitation. The medical center includes St. David's Hospital (acute care) and St. David's Rehabilitation Center (physical medicine and rehabilitation). For more information, please visit

Media Contacts:

Erin Ochoa and Kristin Marcum

Elizabeth Christian & Associates Public Relations


SOURCE The Texas Cardiac Arrhythmia Institute at St. David?sMedical Center
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Vical Receives NIH Grant for an Immunotherapeutic Herpes DNA Vaccine; Herpes Experts at University of Washington and University of Texas to Conduct Preclinical Development
2. Texas Heart(R) Institute at St. Lukes Episcopal Hospital Initiates First Clinical Trial in the World to Treat a Heart Attack Patient with a Special Stem Cell Type
3. Caliper Life Sciences Optical Imaging Technology Selected to Aid Tuberculosis Research Efforts by the Texas A&M Health Science Center
4. Personalized Medicine - The Genomic Revolution in Cardiac Care
5. FAU Receives Patent for Invention Which Induces and Restores Cardiac Muscle Function
6. Signalife Completes Testing of Modules for Holter and Intra-Cardiac Monitor
7. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
8. Study Shows Vernakalant Hydrochloride is Effective in Conversion to Normal Heart Rhythm in Atrial Fibrillation Patients Following Cardiac Surgery
9. FDA Concludes There is No Increased Risk of Cardiac Events for Patients Treated with omeprazole and NEXIUM(R) (esomeprazole magnesium)
10. Do-It-Yourself Cardiac Bypass Surgery: All You Need is Walking Shoes
11. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
Post Your Comments:
(Date:11/25/2015)... AVIV, Israel , November 25, 2015 ... (NASDAQ: KTOV ) (TASE: KTOV), a biopharmaceutical company ... simultaneous treatment of various clinical conditions, today announced the ... 3,158,900 American Depository Shares ( ADSs ), each representing ... purchase up to 3,158,900 ADSs. The ADSs and warrants ...
(Date:11/25/2015)... Nov. 25, 2015 Allergan plc (NYSE: ... and Rugen Therapeutics, a start-up  biotechnology company focused ... CNS disorders and funded by the F-Prime Biomedical ... entered into an exclusive collaboration to support the ... Spectrum Disorders (ASD) and Obsessive Compulsive disorders (OCD). ...
(Date:11/25/2015)... TEL AVIV, Israel , November 25, 2015 /PRNewswire/ ... firms (the "New Investors"), pursuant to which BioLight and ... in BioLight,s IOPtima Ltd. subsidiary ("IOPtima") via a private ... global commercialization of its innovative IOPtimate™ system used in ... a regulatory approval pathway process for the IOPtimate™ system ...
Breaking Medicine Technology:
(Date:11/25/2015)... MN (PRWEB) , ... November 25, 2015 , ... Finnleo, ... through Christmas Eve on several models of traditional and far-infrared saunas. , ... Nordic Spruce is the most traditional Finnish sauna wood, and Finnleo uses only European ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dr. John Pierce, Medical Director at ... hair loss treatment with the Capillus272™ Pro laser therapy cap. FDA cleared for safety ... fuller hair, without the need for surgery, prescription pills, or topical foams. , ...
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, ... Two Organizations, One Beat ” campaign. The partnership between the two groups began in ... in MAP International’s cause. , MAP International was founded in 1954 and is an ...
(Date:11/25/2015)... ... 2015 , ... Dental professionals who would like to become more proficient on ... Dr. Mark Iacobelli’s Advanced Implant Mentoring (AIM) CE course. Courses will be held on ... co-founders of Advanced Implant Mentoring (AIM), Dr. Iacobelli and Dr. D’Orazio are proud to ...
(Date:11/25/2015)... IL (PRWEB) , ... November 25, 2015 , ... The ... announce a recent successful appellate decision obtained by Attorneys Francisco J. Botto and Alex ... Adcock v. Illinois Workers’ Compensation Comm’n, 2015 IL App (2d) 130884WC. , According to ...
Breaking Medicine News(10 mins):